Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04684654 · ClinicalTrials.gov registry record · Phase 1
BMS-986325 in Healthy Participants and Participants With Primary Sjögren's Syndrome
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 1
- Development phase
- 118
- Enrollment target
NCT04684654 is a Phase 1 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 118 participants.
The verdict
NCT04684654, a Phase 1 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 118 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, drug levels, and drug effects of BMS-986325 in healthy participants and participants with primary Sjögren's syndrome. The results will guide the future clinical development with BMS-986325.
Interventions
- BIOLOGICAL BMS-986325
- OTHER Placebo for BMS-986325
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2021-02-16 |
| Est. Completion | 2023-07-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04684654
The ClinicalTrials.gov registry entry for NCT04684654 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 118 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BMS-986325 is the first listed.
NCT04684654 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04684654 about?
NCT04684654 is a clinical study titled "BMS-986325 in Healthy Participants and Participants With Primary Sjögren's Syndrome". The purpose of this study is to evaluate the safety, tolerability, drug levels, and drug effects of BMS-986325 in healthy participants and participants with primary Sjögren's syndrome. The results will guide the future clinical development with BMS-986325.
What is the current status of trial NCT04684654?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 118 participants. The study started on 2021-02-16. Estimated completion is 2023-07-25.
What interventions are being tested in trial NCT04684654?
The interventions under investigation include: BMS-986325 (BIOLOGICAL), Placebo for BMS-986325 (OTHER).
Who is sponsoring clinical trial NCT04684654?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.